Veradermics, Inc SEC filings MANE
Veradermics, Inc has 97 filings in SEC EDGAR's recent list, going back to Oct 9, 2020. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| EFFECT | Filing | Aug 14, 2026 | — |
| 424B3 | Prospectus | Aug 14, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| S-1 | Registration statement | Aug 7, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 15, 2026 | Jul 15, 2026 |
| D | Filing | May 15, 2026 | — |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 1, 2026 | May 1, 2026 |
| 424B4 | Prospectus | Apr 30, 2026 | — |
| FWP | Free writing prospectus | Apr 30, 2026 | — |
| EFFECT | Filing | Apr 29, 2026 | — |
| S-1MEF | Filing | Apr 29, 2026 | — |
| FWP | Free writing prospectus | Apr 27, 2026 | — |
| CORRESP | Letter to the SEC | Apr 27, 2026 | — |
| CORRESP | Letter to the SEC | Apr 27, 2026 | — |
| S-1 | Registration statement | Apr 27, 2026 | — |
| 8-K |
Current report
Results of operations
|
Apr 27, 2026 | Apr 27, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 27, 2026 | Apr 27, 2026 |
| UPLOAD | Letter from the SEC | Apr 7, 2026 | — |
| DRS | Filing | Apr 6, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
| S-8 | Employee stock plan registration | Feb 5, 2026 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 5, 2026 | Feb 5, 2026 |
| 424B4 | Prospectus | Feb 4, 2026 | — |
| CERT | Nyse certification | Feb 4, 2026 | — |
| S-1MEF | Filing | Feb 3, 2026 | — |
| 8-A12B | Filing | Feb 3, 2026 | — |
| FWP | Free writing prospectus | Feb 3, 2026 | — |
| EFFECT | Filing | Jan 30, 2026 | — |
| S-1/A | Amended registration statement | Jan 28, 2026 | — |
| S-1 | Registration statement | Jan 9, 2026 | — |
| D | Filing | Oct 28, 2025 | — |
| DRS | Filing | Oct 27, 2025 | — |
| D | Filing | Dec 10, 2024 | — |
| D | Filing | May 1, 2023 | — |
| D/A | Filing | Oct 7, 2021 | — |
| D | Filing | Oct 6, 2021 | — |
| D | Filing | Oct 9, 2020 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MANE (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1827635
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.